{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:54Z","timestamp":1791313674327,"version":"4.3.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Brexucabtagene autoleucel (brexu-cel) is the anti-CD19 chimeric antigen receptor CAR T-cell (CAR-T) therapy approved for the treatment of relapsed\/refractory (R\/R) mantle cell lymphoma (MCL). Our study, conducted in the scope of the French DESCAR-T registry, aimed to analyze outcomes of MCL after brexu-cel failure. In the DESCAR-T registry, 178 patients with R\/R MCL received brexu-cel. After a median follow-up (FU) of 14.5 months, 61 experienced failures. This study analyzes post\u2013 CAR-T failure progression-free survival (PFS2) and overall survival (OS2), according to clinical characteristics and salvage treatments. At infusion, 36% of patients had a high MCL International Prognostic Index score, 76.2% a Ki-67 index of \u226530%, 30.2% a TP53 mutation, and 31.6% a blastoid variant. After a median FU of 15 months following failure, median OS2 and PFS2 were 5.8 and 1.8 months, respectively. Patients experiencing early failure (&amp;lt;3 months) had a median OS2 of 1.8 months, compared with 6.7 and 9 months for those relapsing within 3 to 6 and after 6 months, respectively. Forty-nine patients received salvage therapy: 16 lenalidomide with\/without rituximab (Len\/R2), 13 immunochemotherapy (ICT), 8 Bruton tyrosine kinase inhibitor with\/without venetoclax (BTKi\/Ven), 7 bispecific T-cell engagers (TCEs), 3 another targeted therapy, and 2 received radiation. Overall, post salvage response rate (ORR) was 20%. One-year OS2 was 36% for patients treated with Len\/R2 and ICT, 57% for TCEs, and 0% for other types of salvage. Notably, none of the TCE responders have relapsed to date (duration of response : 100%). Our series highlights the poor outcomes of patients with MCL after CAR-T failure and suggests a potential benefit of bispecific antibodies in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017234","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:00:11Z","timestamp":1759262411000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group"],"prefix":"10.1182","volume":"10","author":[{"given":"Marion","family":"Aymard","sequence":"first","affiliation":[{"name":"1Department of Hematology, Institut Curie, Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Necker Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rennes University Hospital - Hospital Pontchaillou, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cuozzo","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, Lymphoma Academic Research Organisation, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Gat","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, Lymphoma Academic Research Organisation, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Saint-Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Saint Antoine Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Roulin","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Henri Mondor Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Bordeaux University hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Safar","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5591","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Fayard","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-683X","authenticated-orcid":false,"given":"Gabriel","family":"Brisou","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-3874","authenticated-orcid":false,"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Necker Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Montpellier University Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"17Laboratory of Translational Imaging in Oncology U1288, Institut Curie, Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-9304","authenticated-orcid":false,"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Institut Curie, Saint-Cloud, France"},{"name":"17Laboratory of Translational Imaging in Oncology U1288, Institut Curie, Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"26","key":"2026011308462990000_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"2026011308462990000_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2026011308462990000_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"2026011308462990000_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026011308462990000_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2023-174273","article-title":"Outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study","volume":"142","author":"Goy","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026011308462990000_bib6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026011308462990000_bib7","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2026011308462990000_bib8","first-page":"3745","article-title":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","volume":"109","author":"Herbaux","year":"2024","journal-title":"Haematologica"},{"issue":"14","key":"2026011308462990000_bib9","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026011308462990000_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2023-179269","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics","volume":"142","author":"Kambhampati","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011308462990000_bib11","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2023-182415","article-title":"Real world results of brexucabtagene autoleucel for patients with relapsed\/refractory mantle cell lymphoma - first German\/Swiss analysis","volume":"142","author":"Hess","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026011308462990000_bib12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bjh.19961","article-title":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: results from CART-SIE study","volume":"206","author":"Stella","year":"2025","journal-title":"Br J Haematol"},{"key":"2026011308462990000_bib13","unstructured":"French register of patients with hemopathy eligible for CAR-T cell treatment (DESCAR-T). ClinicalTrials.gov identifier: NCT04328298. Updated 27 January 2025. Accessed 14 October 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04328298."},{"issue":"suppl 1","key":"2026011308462990000_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2024-192995","article-title":"Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: a multicenter analysis","volume":"144","author":"Epstein-Peterson","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011308462990000_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2023-177703","article-title":"Glofitamab monotherapy in patients with non-Hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the Bicar study, a phase II LYSA study","volume":"142","author":"Sesques","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026011308462990000_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026011308462990000_bib17","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2023-173946","article-title":"GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011308462990000_bib18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2026011308462990000_bib19","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"2026011308462990000_bib20","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/75\/2478336\/blooda_adv-2025-017234-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/75\/2478336\/blooda_adv-2025-017234-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:46:42Z","timestamp":1768312002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/75\/547531\/Outcome-of-patients-with-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017234","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,30]]}}}